Clinical trials: Nonalcoholic Fatty Liver
Type2 Diabetes, Fatty Liver, Nonalcoholic
Mechanism of Serum PRL in the Development of MAFLD
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently.
- Conditions
- Type2 Diabetes, Fatty Liver, Nonalcoholic, Liver Fibrosis
- Trial name
- NCT05525884
- Testing
- non-invasive method, Fibroscan
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Shen Qu
Fasting, Intermittent, Diet
Intermittent Fasting Versus Diet to Stop Hypertension on Metabolic Risk Profile in Nonalcoholic Fatty Liver Patients
This study was conducted to compare between the effect of intermittent fasting and diatery approach to stop hypertension on metabolic risk profile in nonalcoholic fatty liver patients.
- Conditions
- Fasting, Intermittent, Diet, Hypertension, Metabolic Syndrome
- Trial name
- NCT06666894
- Testing
- Intermittent fasting, Dietary approach to stop hypertension (DASH)
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Colorectal Adenoma, Colorectal Neoplasm
ObeSity Related Colorectal Adenoma Risk
In the UK, around 1 in 16 men and 1 in 20 women will develop bowel cancer at some point in their lives. Most bowel cancers happen when a type of growth in the bowel called an adenoma eventually becomes cancerous.
- Conditions
- Colorectal Adenoma, Colorectal Neoplasm, Colorectal Cancer, Obesity
- Trial name
- OSCAR (NCT03663062)
- Testing
- Colonoscopy
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,430 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
Non-Alcoholic Fatty Liver Disease
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
Lovaza is the only fish oil supplement approved by the FDA. It is available by prescription for the treatment of hypertriglyceridemia (> 500 mg/dl).
- Trial name
- NCT00941642
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Huntington Medical Research Institutes
Non-Alcoholic Fatty Liver Disease (NAFLD
Interest of APA in Fatty Liver Disease Evaluation of Efficacy and Adherence to an Adapted Physical Activity (APA) Program in Patients With Metabolic Fatty Liver Disease
Non-Alcoholic Fatty liver Disease (NAFLD) is a Public Health problem. NAFLD affects nearly 25% of the world's population. NAFLD includes hepatic complications related to insulin resistance and metabolic inflammation.
- Trial name
- STEATO-APA (NCT04835831)
- Testing
- adapted physical activity + Dietetic advice
- Where
- 2 sites in France
- Volunteers
- 115 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
FATTY LIVER, NO MALIGNANCY
Telomere Parameters in Patients With Nonalcoholic Fatty Liver
Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis.
- Conditions
- FATTY LIVER, NO MALIGNANCY, NO DECOMPENSATED ILLNESS
- Trial name
- telomereFL (NCT01694342)
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
NAFLD
Study of Losartan in the Treatment of NAFLD in Children
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease among children and is closely associated with obesity and the metabolic syndrome.
- Trial name
- NCT01913470
- Testing
- Losartan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Miriam Vos, MD
Non-alcoholic Steatohepatitis
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is…
- Trial name
- NCT03987451
- Testing
- Semaglutide
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Non-Alcoholic Steatohepatitis
A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of HEC96719 in non-cirrhotic NASH patients.
- Trial name
- NCT05397379
- Testing
- HEC96719
- Where
- 9 sites in China
- Volunteers
- 68 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Sensitivity to Thyroid Hormones, Metabolic Parameters
Effects of Intermittent Fasting on Fatty Liver Disease
Eighty subjects with FLD were recruited from the endocrinology clinic at Beijing Chao-yang Hospital. All of the following inclusion criteria needed to be met: hepatic fat content (HFC) were upper 5.0% evaluated by upper abdominal…
- Conditions
- Sensitivity to Thyroid Hormones, Metabolic Parameters, in Patients With FLD
- Trial name
- NCT04795973
- Testing
- 5:2 intermittent fasting
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Chao Yang Hospital
NASH - Nonalcoholic Steatohepatitis, Insulin Sensitivity
Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH
Non-alcoholic steato-hepatitis (NASH) affects up to 3% of the population and leads to liver cirrhosis, hepatocellular carcinoma (HCC) and death. The only known treatment is weight loss and exercise.
- Trial name
- ELVIS (NCT03490370)
- Testing
- Electro-muscular stimulation using NeuroTrac MyoPlus 2/4
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- NHS Tayside
Non-alcoholic Fatty Liver Disease, Diabetes
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease
The worldwide epidemic of obesity is paralleled with increased cases of non-alcoholic liver disease (liver fat accumulation) and diabetes.
- Trial name
- LINC (NCT00714129)
- Testing
- Dietary intervention (calorie restricted diet)
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the…
- Conditions
- Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
- Trial name
- SAMARA (NCT06005012)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
NAFLD
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity which can progress to deadly complications like end-stage liver disease and hepatocellular carcinoma.
- Trial name
- NCT04861571
- Testing
- Dietary intervention with very low calorie diet (VLCD), Control Arm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Permeability; Increased, NAFLD
Evaluation of Gut Permeability in Patients Affected by Obesity and NAFLD: Influence of Ketogenic Diet.
This study is open label, with one arm only. In this study will be enrolled patients with obesity (BMI more than 30). Aim of the study is to determine the influence (if any) of a very low calorie ketogenic diet (VLCKD) on gut…
- Conditions
- Permeability; Increased, NAFLD, Obesity
- Trial name
- NCT05477212
- Testing
- Ketogenic Diet
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Fatty Liver, Nonalcoholic, Insulin Sensitivity
Determinants of Liver Fat Composition
Excessive fat in the liver, in absence of high alcohol consumption, is diagnosed as non-alcoholic fatty liver (NAFL). NAFL prevalence is as high as 50-70% in obese people and is associated with impairments in metabolic health…
- Trial name
- NCT03211299
- Where
- Netherlands
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
NASH - Nonalcoholic Steatohepatitis
LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.
- Trial name
- NCT04328077
- Testing
- TERN-101
- Where
- 31 sites in United States
- Volunteers
- 101 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Diabetes, Fatty Liver
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
Background: Vitamin E is an antioxidant that reduces the damaging effects of oxygen in the body. Most American men (90%) and women (96%) do not get enough vitamin E from their diets; however, the amount of vitamin E needed by the…
- Conditions
- Diabetes, Fatty Liver, Obesity, Healthy Volunteers
- Trial name
- NCT00862433
- Testing
- Alpha tocopherol, Vitamin E, Vitamin C
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease
Investigation on Safety and Efficacy of Soybean Fermented Extract (MBS217) in Treating Patients With NAFLD
Investigators aimed to investigate the efficacy and safety of fermented soybean extract (MBS-217) in treating participants with Non-alcoholic fatty liver disease (NAFLD) in this study.
- Trial name
- NCT05686174
- Testing
- MBS217
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.